Case Report
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Feb 16, 2023; 11(5): 1165-1174
Published online Feb 16, 2023. doi: 10.12998/wjcc.v11.i5.1165
Bladder preservation in complicated invasive urothelial carcinoma following treatment with cisplatin/gemcitabine plus tislelizumab: A case report
Rui Yang, Jun-Xing Chen, Shu-Hang Luo, Ting-Ting Chen, Ling-Wu Chen, Bin Huang
Rui Yang, Jun-Xing Chen, Shu-Hang Luo, Ling-Wu Chen, Bin Huang, Department of Urology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, Guangdong Province, China
Ting-Ting Chen, The Medical Department, 3D Medicines Inc., Shanghai 200120, China
Author contributions: Huang B contributed to conceptualization; Chen JX and Chen LW conducted the investigation; Yang R prepared the original draft; Luo SH wrote and reviewed the manuscript; Yang R and Chen TT edited the manuscript; All authors have read the article and approved the submitted version.
Informed consent statement: Written informed consent was obtained from the patient for the publication of any potentially identifiable images or data included in this article.
Conflict-of-interest statement: Author Ting-Ting Chen was employed by the company 3D Medicines Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
CARE Checklist (2016) statement: The authors have read CARE Checklist (2016), and the manuscript was prepared and revised according to CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bin Huang, MD, PhD, Doctor, Department of Urology, The First Affiliated Hospital of Sun Yat-Sen University, No. 58 Zhong Shan 2nd Road, Guangzhou 510080, Guangdong Province, China. huangb48@mail.sysu.edu.cn
Received: November 4, 2022
Peer-review started: November 4, 2022
First decision: December 13, 2022
Revised: December 25, 2022
Accepted: January 20, 2023
Article in press: January 20, 2023
Published online: February 16, 2023
Processing time: 101 Days and 20.5 Hours
Core Tip

Core Tip: Urothelial carcinoma (UC) with complicated differentiation is highly malignant, and radical cystectomy (RC) is the preferred treatment. Because of the complications related to RC, bladder-sparing therapy has become a research hotspot. We here report a patient who was diagnosed with muscle-invasive bladder cancer with squamous and glandular differentiation and positive programmed cell death-ligand 1 (PD-L1) expression. The patient received a combination of chemotherapy and immunotherapy and achieved bladder preservation and has maintained tumor-free for over two years. This case highlights that the combination treatment might be an effective and safe strategy for UC with divergent histologic differentiation and positive PD-L1 expression.